Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAI...
Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia
About this item
Full title
Author / Creator
Ren, Jun , Huang, Junpeng , Yang, Zailin , Sun, Minghui , Yang, Jing , Lin, Can , Jin, Fangfang , Liu, Yongcan , Tang, Lisha , Hu, Jiayuan , Wei, Xingyu , Chen, Xinyi , Yuan, Zihao , Yang, Zesong , Chen, Yanmeng and Zhang, Ling
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor outcomes, especially in older AML patients. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is considered a promising anticancer drug because it selectively induces the extrinsic apoptosis of tumor cells without affecting normal cells. However, clinical trials have...
Alternative Titles
Full title
Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1fea17938b884041ac06de0e085d5857
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1fea17938b884041ac06de0e085d5857
Other Identifiers
ISSN
1756-9966,0392-9078
E-ISSN
1756-9966
DOI
10.1186/s13046-024-03100-0
